The stock's fall snapped a three-day winning streak.

Biogen Inc. closed 44.90% short of its 52-week high of $238.00, which the company achieved on July 12th.

Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

It has been about a month since the last earnings report for Krystal Biotech, Inc. (KRYS). Shares have lost about 3.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug ...

Inspired by her own mother's battle, Dr. Lauren Powell is on a mission to improve care for lupus patients of all backgrounds.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief ...